Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ร-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania.
Frequently asked questions
What sector does Passage Bio, Inc (PASG) operate in?
Passage Bio, Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Passage Bio, Inc (PASG) current stock price?
As of the latest data, Passage Bio, Inc stock price is $3.31, with a previous close of $3.36. Passage Bio, Inc lost -$0.05 in the last trading session, representing a -1.46% loss.
What is Passage Bio, Inc (PASG) current market capitalization?
Passage Bio, Inc market cap is approximately 10.65 million.
What is Passage Bio, Inc (PASG) Earnings Per Share (EPS)?
The trailing EPS is -$11.32, and the forward EPS is -$10.39.
What is Passage Bio, Inc (PASG) EBITDA?
Passage Bio, Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -7.79 million.
Does Passage Bio, Inc (PASG) pay dividends?
No. Passage Bio, Inc does not pay a dividend.
When is Passage Bio, Inc (PASG) next earnings report?
Passage Bio, Inc is expected to release its next earnings report on September 30, 2026.
What is Passage Bio, Inc (PASG) beta (volatility) score?
Passage Bio, Inc has a beta of 1.429, suggesting it is more volatile than the market.
